Skip to main content

Advertisement

Table 1 Plasmodium ovale spp. cases

From: A cluster of the first reported Plasmodium ovale spp. infections in Peru occuring among returning UN peace-keepers, a review of epidemiology, prevention and diagnostic challenges in nonendemic regions

Patient Service Age Episodes P. falciparum (+) in CAR Primary treatment regimen Delay in presentation (months) Presenting complaint Lab abnormalities Parasitemia (parasites/µl) Diagnosis Treatment regimen
1a Navy 44 1 Artemether 80 mg lumefantrine 480 mg < 1 BP; (F, HA, GF)a None 778 PCR microscopy Chloroquine 250 mg primaquine 30 mg (14 days)
2b Army 38 1 Artemether 80 mg lumefantrine 480 mg 11 F, HA, M, A Th, Tr, IHB 27,339 PCR microscopy Chloroquine 250 mg primaquine 30 mg (7 days)
3 Army 44 1 Artemether 80 mg lumefantrine 480 mg 11 F, HA, M Th, Tr, IHB 433 Microscopy Chloroquine 250 mg primaquine 30 mg (7 days)
4 Army 50 2 Artemether 80 mg lumefantrine 480 mg 11 F, HA, GF, T Tr 481 Microscopy Chloroquine 250 mg primaquine 30 mg (7 days)
  1. Delayed presentation time in months from date of return to Peru to seeking care
  2. CAR Central Africa Republic, PCR polymerase chain reaction, BP back pain, F fever, HA headache, M myalgia, A arthralgia, GF general fatigue, T thoracic pain, Th thrombocytopenia, Tr transaminitis, IHB indirect hyperbilirubinemia
  3. aPatient with P. ovale. curtisi, originally presented with BP 5 days after returning from CAR, symptoms then continued intermittently until April 2017 when diagnosis was made after 2 weeks HA, at 3½ months was admitted with F, BP, M
  4. bPatient with P. ovale. wallikeri (MIS2712)